J Peter Donnelly

List of Publications by Year
in descending order

233 papers	23,530 citations	19657 61 h-index	7950 149 g-index
239 all docs	239 docs citations	239 times ranked	17352 citing authors

#	Article	IF	Citations
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
2	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases, 2002, 34, 7-14.	5.8	2,255
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
4	Perspectives on cancer therapy-induced mucosal injury. Cancer, 2004, 100, 1995-2025.	4.1	1,214
5	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical Microbiology and Infection, 2012, 18, 19-37.	6.0	977
6	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer, 2011, 47, 8-32.	2.8	895
7	Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infectious Diseases, The, 2004, 4, 349-357.	9.1	449
8	EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clinical Microbiology and Infection, 2008, 14, 398-405.	6.0	447
9	Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 89-96.	9.1	310
10	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection, 2012, 18, 9-18.	6.0	310
11	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection, 2012, 18, 53-67.	6.0	280
12	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. Clinical Microbiology and Infection, 2012, 18, 38-52.	6.0	264
13	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
14	Aspergillus PCR: One Step Closer to Standardization. Journal of Clinical Microbiology, 2010, 48, 1231-1240.	3.9	251
15	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	3.2	230
16	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplantation, 2000, 25, 1269-1278.	2.4	226
17	Early Stop Polymorphism in Human DECTINâ€1 Is Associated with IncreasedCandidaColonization in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2009, 49, 724-732.	5.8	226
18	ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2386-2396.	3.0	226

#	Article	IF	Citations
19	ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2016, 71, 2397-2404.	3.0	211
20	Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial. Annals of Internal Medicine, 1994, 120, 834.	3.9	203
21	Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method. Journal of Clinical Microbiology, 2000, 38, 2949-2954.	3.9	203
22	Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. Journal of Clinical Microbiology, 1997, 35, 257-260.	3.9	201
23	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virusâ€"Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2013, 57, 794-802.	5.8	196
24	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy, 2018, 73, 3221-3230.	3.0	186
25	SEPTICAEMIA CAUSED BY VIRIDANS STREPTOCOCCI IN NEUTROPENIC PATIENTS WITH LEUKAEMIA. Lancet, The, 1983, 322, 1452-1454.	13.7	174
26	Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia. Annals of Pharmacotherapy, 2005, 39, 32-38.	1.9	168
27	Optimization of the Cutoff Value for the Aspergillus Double-Sandwich Enzyme Immunoassay. Clinical Infectious Diseases, 2007, 44, 1329-1336.	5.8	163
28	AspergillusPolymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. Clinical Infectious Diseases, 2015, 61, 1293-1303.	5.8	157
29	Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 3402-3408.	3.9	148
30	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration. Cancer, 2005, 103, 191-199.	4.1	145
31	Evaluation of Aspergillus PCR Protocols for Testing Serum Specimens. Journal of Clinical Microbiology, 2011, 49, 3842-3848.	3.9	140
32	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical Microbiology and Infection, 2003, 9, 467-474.	6.0	135
33	Prophylaxis and Aspergillosis â€" Has the Principle Been Proven?. New England Journal of Medicine, 2007, 356, 409-411.	27.0	128
34	Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clinical Microbiology and Infection, 2003, 9, i-viii.	6.0	122
35	Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia. Antimicrobial Agents and Chemotherapy, 2007, 51, 3599-3604.	3.2	119
36	Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clinical Infectious Diseases, 2015, 61, 324-331.	5.8	117

#	Article	IF	Citations
37	Therapeutic Drug Monitoring of Voriconazole. Therapeutic Drug Monitoring, 2008, 30, 403-411.	2.0	116
38	Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infectious Diseases, The, 2003, 3, 405-412.	9.1	115
39	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	6.0	113
40	Polymerase Chain Reaction for Diagnosing Invasive Aspergillosis: Getting Closer but Still a Ways to Go. Clinical Infectious Diseases, 2006, 42, 487-489.	5.8	112
41	Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative. Journal of Clinical Microbiology, 2015, 53, 2832-2837.	3.9	105
42	Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplantation, 2004, 34, 193-196.	2.4	104
43	Efficacy of Itraconazole in the Prevention of Fungal Infections Among Neutropenic Patients with Hematologic Malignancies and Intensive Chemotherapy. A Double Blind, Placebo Controlled Study. Leukemia and Lymphoma, 1993, 11, 353-358.	1.3	101
44	Critical Stages of Extracting DNA from Aspergillus fumigatus in Whole-Blood Specimens. Journal of Clinical Microbiology, 2010, 48, 3753-3755.	3.9	92
45	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clinical Microbiology and Infection, 2012, 18, 1-8.	6.0	91
46	Voriconazoleâ€"a new therapeutic agent with an extended spectrum of antifungal activity. Clinical Microbiology and Infection, 2004, 10, 107-117.	6.0	90
47	Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Medicine, 2009, 7, 44.	5.5	90
48	Role of the Mycobiome in Human Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 329-332.	2.0	87
49	Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy, 1995, 36, 185-200.	3.0	83
50	Intestinal Damage Determines the Inflammatory Response and Early Complications in Patients Receiving Conditioning for a Stem Cell Transplantation. PLoS ONE, 2010, 5, e15156.	2.5	83
51	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clinical Microbiology and Infection, 2012, 18, 68-77.	6.0	81
52	Serial monitoring ofAspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection, 1997, 25, 86-89.	4.7	80
53	Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplantation, 2009, 44, 495-507.	2.4	77
54	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clinical Infectious Diseases, 2015, 60, 713-720.	5.8	75

#	Article	IF	Citations
55	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.. Journal of Antimicrobial Chemotherapy, 1998, 42, 389-392.	3.0	71
56	Human Platelets AttenuateAspergillusSpecies via Granuleâ€Dependent Mechanisms. Journal of Infectious Diseases, 2008, 198, 1243-1246.	4.0	71
57	Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation. Antimicrobial Agents and Chemotherapy, 2006, 50, 4096-4102.	3.2	67
58	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. Journal of Antimicrobial Chemotherapy, 2017, 72, 2359-2367.	3.0	65
59	Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplantation, 2005, 36, 703-707.	2.4	64
60	Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplantation, 2009, 43, 55-60.	2.4	64
61	Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemiaâ€"ciprofloxacin versus co-trimoxazole plus colistin. European Journal of Cancer, 1992, 28, 873-878.	2.8	63
62	Role of curcumin and the inhibition of NF-ÎºB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia, 2004, 18, 276-284.	7.2	63
63	Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplantation, 2013, 48, 1465-1471.	2.4	62
64	Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy. Annals of Oncology, 2010, 21, 1706-1711.	1.2	60
65	The role of antifungal treatment in hematology. Haematologica, 2012, 97, 325-327.	3.5	60
66	Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 387-392.	2.3	58
67	Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2014, 16, 279-285.	1.7	58
68	NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2009, 44, 243-248.	2.4	57
69	A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplantation, 1992, 9, 409-13.	2.4	56
70	Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplantation, 2005, 35, 707-711.	2.4	55
71	Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 1994, 22, 81-85.	4.7	54
72	EUCAST technical note on anidulafungin. Clinical Microbiology and Infection, 2011, 17, E18-E20.	6.0	53

#	Article	IF	Citations
73	Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy, 1991, 35, 672-678.	3.2	52
74	Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?. Journal of Antimicrobial Chemotherapy, 1996, 37, 389-390.	3.0	52
75	Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species. Antimicrobial Agents and Chemotherapy, 2009, 53, 1628-1629.	3.2	52
76	Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. Journal of Hospital Infection, 1984, 5, 83-91.	2.9	51
77	Two Strategies for Managing Invasive Aspergillosis: A Decision Analysis. Clinical Infectious Diseases, 1997, 25, 1148-1154.	5.8	51
78	EUCAST Technical Note on voriconazole. Clinical Microbiology and Infection, 2008, 14, 985-987.	6.0	51
79	Measuring mucosal damage induced by cytotoxic therapy. Supportive Care in Cancer, 2004, 12, 227-233.	2.2	50
80	Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplantation, 2008, 42, 345-349.	2.4	50
81	Procalcitonin Does Not Discriminate Infection from Inflammation after Allogeneic Bone Marrow Transplantation. Vaccine Journal, 2000, 7, 889-892.	2.6	49
82	Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). Journal of Clinical Microbiology, 2007, 45, 109-111.	3.9	49
83	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses, 2011, 54, e449-55.	4.0	49
84	Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Supportive Care in Cancer, 2013, 21, 1621-1627.	2.2	49
85	Paradoxical Increase in CirculatingAspergillusAntigen during Treatment with Caspofungin in a Patient with Pulmonary Aspergillosis. Clinical Infectious Diseases, 2006, 43, e23-e25.	5.8	48
86	Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. Annals of Oncology, 2009, 20, 337-342.	1.2	48
87	18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 120-128.	6.4	48
88	Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips. Medical Mycology, 2018, 56, S60-S72.	0.7	46
89	Antifungal Prophylaxis during Neutropenia or Allogeneic Bone Marrow Transplantation: What is the State of the Art?. Chemotherapy, 1992, 38, 43-49.	1.6	44
90	Safe living after hematopoietic cell transplantation. Bone Marrow Transplantation, 2009, 44, 509-519.	2.4	44

#	Article	IF	Citations
91	Duration of Antifungal Treatment and Development of Delayed Complications in Patients with Candidaemia. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 43-48.	2.9	41
92	Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 977-981.	2.4	41
93	Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. British Journal of Haematology, 2011, 153, 681-697.	2.5	40
94	Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 1888-1894.	3.2	40
95	Analytical Comparison of In Vitro -Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative. Journal of Clinical Microbiology, 2015, 53, 2838-2845.	3.9	40
96	EUCAST breakpoints for antifungals. Drug News and Perspectives, 2010, 23, 93.	1.5	40
97	Failure of Clindamycin to Influence the Course of Severe Oromucositis Associated with Streptococcal Bacteraemia in Allogeneic Bone Marrow Transplant Recipients. Scandinavian Journal of Infectious Diseases, 1993, 25, 43-50.	1.5	39
98	Bacterial complications of transplantation: diagnosis and treatment. Journal of Antimicrobial Chemotherapy, 1995, 36, 59-72.	3.0	39
99	Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. European Journal of Cancer, 1996, 32, 1332-1339.	2.8	39
100	A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Supportive Care in Cancer, 2005, 13, 790-796.	2.2	39
101	The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay. Medical Mycology, 2020, 58, 779-788.	0.7	39
102	The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. Clinical Immunology, 2010, 136, 302-306.	3.2	38
103	Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. British Journal of Haematology, 2002, 117, 259-264.	2.5	37
104	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology, 1995, 70, 83-87.	1.8	36
105	Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 2010, 65, 107-113.	3.0	36
106	Serum C-reactive protein levels in the management of infection in acute leukaemia. European Journal of Cancer & Clinical Oncology, 1984, 20, 319-325.	0.7	35
107	Ceftazidime as first-line therapy for fever in acute leukaemia. Journal of Infection, 1985, 11, 205-215.	3.3	34
108	Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clinical Microbiology and Infection, 2001, 7, 47-52.	6.0	32

#	Article	IF	Citations
109	Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Annals of Hematology, 2006, 85, 621-623.	1.8	32
110	New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. Journal of Fungi (Basel, Switzerland), 2019, 5, 9.	3.5	32
111	Reliability of clinical research on invasive fungal infections: a systematic review of the literature. Medical Mycology, 2001, 39, 35-40.	0.7	30
112	Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagnostic Microbiology and Infectious Disease, 2009, 64, 408-415.	1.8	30
113	The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, doubleâ€blind, placeboâ€controlled, randomized, phase III clinical trial. Journal of Oral Pathology and Medicine, 2012, 41, 229-234.	2.7	30
114	Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1389-1394.	3.0	30
115	Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clinical Microbiology and Infection, 2009, 15, 380-386.	6.0	29
116	Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. Journal of Antimicrobial Chemotherapy, 1993, 31, 813-829.	3.0	28
117	Bacteremia Due to Oral Viridans Streptococci in Neutropenic Patients with Cancer: Cytostatics Are a More Important Risk Factor than Antibacterial Prophylaxis. Clinical Infectious Diseases, 1995, 20, 469-470.	5.8	28
118	Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 179-182.	2.0	28
119	Options and limitations of teicoplanin in febrile granulocytopenic patients. British Journal of Haematology, 1990, 76, 1-5.	2.5	27
120	Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. Reviews in Medical Microbiology, 1996, 7, 105-114.	0.9	27
121	Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: A study by the fungal PCR Initiative and the Modimucor study group. Medical Mycology, 2021, 59, 126-138.	0.7	27
122	Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. The Cochrane Library, 2019, 2019, CD009551.	2.8	27
123	High-dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet, The, 1992, 339, 1117.	13.7	25
124	How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2016, 173, 179-189.	2.5	25
125	Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation, 1990, 5, 179-82.	2.4	25
126	Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. Journal of Antimicrobial Chemotherapy, 1990, 25, 985-993.	3.0	24

#	Article	IF	Citations
127	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What isAspergillus?. Medical Mycology, 2017, 55, myw093.	0.7	24
128	Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 2000, 26, 1131-1132.	2.4	23
129	Potential Sites of Infection That Develop in Febrile Neutropenic Patients. Leukemia and Lymphoma, 1993, 10, 461-467.	1.3	22
130	Pre-emptive administration of corticosteroids prevents the development of ARDS associated withStreptococcus mitis bacteremia following chemotherapy with high-dose cytarabine. Annals of Hematology, 1994, 69, 69-71.	1.8	22
131	A scoring system for the assessment of oral mucositis in daily nursing practice. European Journal of Cancer Care, 2006, 15, 228-234.	1.5	22
132	Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis. Journal of Clinical Microbiology, 2013, 51, 2403-2405.	3.9	22
133	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1166-1174.	3.0	22
134	Can anything be done about oral mucositis?. Annals of Oncology, 2003, 14, 505-507.	1.2	21
135	Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2006, 38, 521-525.	2.4	21
136	Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy. Medical Mycology, 2011, 49, 848-855.	0.7	21
137	An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. Journal of Antimicrobial Chemotherapy, 2013, 68, 1655-1659.	3.0	20
138	Long-Term Health Related Quality of Life following Intensive Care during Treatment for Haematological Malignancies. PLoS ONE, 2014, 9, e87779.	2.5	20
139	Improved Detection of Circulating Aspergillus Antigen by Use of a Modified Pretreatment Procedure. Journal of Clinical Microbiology, 2008, 46, 1391-1397.	3.9	19
140	Galactomannan Detection and Diagnosis of Invasive Aspergillosis. Clinical Infectious Diseases, 2010, 50, 1070-1071.	5.8	19
141	Deferasirox as adjunctive therapy for mucormycosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 519-520.	3.0	19
142	Issues in antifungal stewardship: an opportunity that should not be lost: Table 1. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw506.	3.0	19
143	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. Journal of Clinical Microbiology, 2016, 54, 960-966.	3.9	19
144	Aspergillus fumigatus Pneumonia in Neutropenic Patients During Therapy with Fluconazole for Infection Due to Candida Species. Clinical Infectious Diseases, 1993, 16, 734-735.	5.8	18

#	Article	IF	Citations
145	Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. Annals of Hematology, 1997, 74, 143-147.	1.8	18
146	Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transplant Infectious Disease, 2002, 4, 64-65.	1.7	18
147	An overview of using fungal DNA for the diagnosis of invasive mycoses. Expert Review of Molecular Diagnostics, 2022, 22, 169-184.	3.1	18
148	Consensus definitions for invasive fungal disease: Strengths, limitations, and revisions. Medical Mycology, 2006, 44, 285-288.	0.7	17
149	Halo Sign and Improved Outcome. Clinical Infectious Diseases, 2007, 44, 1666-1667.	5.8	17
150	EUCAST technical note on posaconazole*. Clinical Microbiology and Infection, 2011, 17, E16-E17.	6.0	17
151	Editorial: Celebrating 40 years of the Journal. Journal of Antimicrobial Chemotherapy, 2016, 71, 1-2.	3.0	17
152	Protective environment for hematopoietic cell transplant (HSCT) recipients: The Infectious Diseases Working Party EBMT analysis of global recommendations on health-care facilities. Bone Marrow Transplantation, 2018, 53, 1131-1138.	2.4	17
153	Timely Intervention for Invasive Fungal Disease: Should the Road Now Lead to the Laboratory Instead of the Pharmacy?. Clinical Infectious Diseases, 2009, 48, 1052-1054.	5.8	16
154	Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients. Current Opinion in Infectious Diseases, 2011, 24, 554-563.	3.1	16
155	Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. Journal of Infection, 1986, 13, 125-131.	3.3	15
156	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. Journal of Antimicrobial Chemotherapy, 2007, 60, 385-393.	3.0	15
157	Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2014, 49, 264-269.	2.4	15
158	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	3.0	15
159	The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 2021, 76, 635-638.	3.0	15
160	The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation. Transplant Infectious Disease, 2008, 10, 80-89.	1.7	14
161	Triggers for driving treatment of at-risk patients with invasive fungal disease. Journal of Antimicrobial Chemotherapy, 2013, 68, iii17-iii24.	3.0	14
162	Assessment and reporting of clinical trials of empirical therapy in neutropenic patients. Journal of Antimicrobial Chemotherapy, 1991, 27, 377-387.	3.0	13

#	Article	IF	Citations
163	Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplantation, 2014, 49, 8-10.	2.4	13
164	Pneumocystis jiroveciipneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipientsâ€"authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw580.	3.0	13
165	Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Annals of Hematology, 1991, 63, 195-200.	1.8	12
166	Validating PCR for detecting invasive aspergillosis. British Journal of Haematology, 2004, 127, 235-236.	2.5	12
167	A review of quality assessment of the methodology used in guidelines and systematic reviews on oral mucositis. Journal of Clinical Nursing, 2009, 18, 3-12.	3.0	12
168	Empiric Treatment of Localized Infections in the Febrile Neutropenic Patient with Monotherapy. Leukemia and Lymphoma, 1993, 9, 193-203.	1.3	11
169	Monitoring cyclosporine using blood drawn via a central venous catheter. Bone Marrow Transplantation, 2003, 32, 1037-1037.	2.4	11
170	Providing oral care in haematological oncology patients: Nursesâ€™ knowledge and skills. European Journal of Oncology Nursing, 2008, 12, 291-298.	2.1	11
171	Describing and comparing in-vitro antimicrobial activity by the box-plot technique. Journal of Antimicrobial Chemotherapy, 1992, 30, 713-719.	3.0	10
172	High-Dose Itraconazole for the Treatment of Cerebral Aspergillosis. Clinical Infectious Diseases, 1996, 23, 1196-1197.	5.8	10
173	How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient. European Journal of Cancer Care, 2011, 20, 679-685.	1.5	10
174	Editorial: A new Editor-in-Chief and the 40th anniversary of the Journal of Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1-1.	3.0	10
175	Nucleic Acid Tools for Invasive Fungal Disease Diagnosis. Current Fungal Infection Reports, 2020, 14, 76-88.	2.6	10
176	Host Impairments in Patients with Neoplastic Diseases. Cancer Treatment and Research, 2014, 161, 1-41.	0.5	10
177	Infection in the neutropenic and haematopoietic stem cell transplant recipient. Current Opinion in Infectious Diseases, 2000, 13, 337-342.	3.1	9
178	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2009, 53, 2704-2706.	3.2	9
179	Standardization of Aspergillus PCR diagnosis. Bone Marrow Transplantation, 2012, 47, 299-300.	2.4	9
180	Chemoprophylaxis for the prevention of bacterial and fungal infections. Cancer Treatment and Research, 1995, 79, 45-81.	0.5	9

#	Article	IF	Citations
181	Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. Bone Marrow Transplantation, 1988, 3, 509-12.	2.4	9
182	Determining mucosal barrier injury to the oesophagus using CT scan. Supportive Care in Cancer, 2007, 15, 1105-1108.	2.2	8
183	Continuous non-invasive monitoring of the skin temperature of HSCT recipients. Supportive Care in Cancer, 2010, 18, 37-42.	2.2	8
184	Towards individually tailored empiric antibiotic therapy in febrile granulocytopenic patients. Netherlands Journal of Medicine, 1990, 37, 111-9.	0.5	8
185	The end of the road for empirical antifungal treatment?. Lancet Infectious Diseases, The, 2013, 13, 470-472.	9.1	7
186	Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy. Infection, 1998, 26, 349-354.	4.7	6
187	A strategy for managing fungal infections in haematopoietic stem cell transplantation. Transplant Infectious Disease, 2000, 2, 88-95.	1.7	6
188	Differences in T Cell Depletion and Intestinal Mucositis Explain Inconsistent Effects of NOD2/CARD15 Polymophisms in SCT. Biology of Blood and Marrow Transplantation, 2011, 17, 1421-1423.	2.0	6
189	Issues in genetic association studies: limitations of statistical analysis and biological plausibility. Bone Marrow Transplantation, 2011, 46, 906-907.	2.4	6
190	Symptoms and diagnosis of nosocomial fungal infections – state-of-the-art. European Journal of Medical Research, 2002, 7, 192-9.	2.2	6
191	European Surveillance of Infections in Cancer Patients â€“ ESIC. Chemotherapy, 1999, 45, 237-241.	1.6	5
192	Treatment of Fungal Infections in Surgical Patients Using Conventional Antifungals. Journal of Chemotherapy, 1999, 11, 494-503.	1.5	5
193	European Surveillance of Infections and Risk Factors in Cancer Patients. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 161-163.	2.9	5
194	Host-microbe interactions in stem cell transplantation; recognizing Candida in infection and inflammation. Virulence, 2010, 1, 180-184.	4.4	5
195	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 2011, 5, 128-134.	2.6	5
196	Towards a standard for Aspergillus PCR - requirements, process and results. Infectio, 2012, 16, 64-72.	0.4	5
197	Lymphocyte subsets, granulocyteâ€“colony-stimulating factor responsiveness and post-stem cell transplantation infections: mucositis is the underestimated confounder?. Cytotherapy, 2012, 14, 381-383.	0.7	5
198	Mucosal Barrier Injury and Infections. , 2011, , 167-173.		5

#	Article	IF	Citations
199	Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia. Netherlands Journal of Medicine, 1989, 35, 143-6.	0.5	5
200	Infectious Complications of Cancer: Controversies in the Antibacterial Treatment of Patients with Neutropenia: A Matter of Comprehension or Apprehension?. Cancer Investigation, 1997, 15, 37-46.	1.3	4
201	Commentary on the MAFF technical report: a review of antimicrobial resistance in the food chain. International Journal of Antimicrobial Agents, 1999, 12, 63-65.	2.5	4
202	Reply to Miceli and Anaissie. Clinical Infectious Diseases, 2007, 44, 760-761.	5.8	4
203	Infections in the Immunocompromised Host. , 2015, , 3384-3394.e2.		4
204	BACTERAEMIA AND HICKMAN CATHETERS. Lancet, The, 1985, 326, 48.	13.7	3
205	Limitations of box-plots in summarizing MIC data. Journal of Antimicrobial Chemotherapy, 1994, 33, 1251-1251.	3.0	3
206	Febrile neutropenia: antifungal prophylaxis. International Journal of Antimicrobial Agents, 2000, 16, 127-130.	2.5	3
207	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
208	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2019, 74, 532-533.	3.0	3
209	The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections. Clinical Infectious Diseases, 2021, 72, S77-S78.	5.8	3
210	Challenges and progress in setting a standard for PCR for invasive aspergillosis. Current Fungal Infection Reports, 2008, 2, 232-236.	2.6	2
211	Introduction and aims. Journal of Antimicrobial Chemotherapy, 2013, 68, iii3-iii4.	3.0	2
212	Reply to Mafaciolli and Pasqualotto. Clinical Infectious Diseases, 2020, 71, 2542-2543.	5.8	2
213	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology, 1995, 70, 83-87.	1.8	2
214	Infections in the Immunocompromised Host. , 2010, , 3781-3791.		2
215	Care pathways for managing invasive mould diseases. International Journal of Antimicrobial Agents, 2013, 42, 5-9.	2.5	1
216	Behind the scenes ofJAC: the Editor-in-Chief. Journal of Antimicrobial Chemotherapy, 2016, 71, 1751-1754.	3.0	1

#	Article	IF	Citations
217	Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis. Clinical Microbiology and Infection, 2020, 26, 781.e1-781.e8.	6.0	1
218	Infection Prevention â€“ Protected Environment and Infection Control. , 2011, , 541-550.		1
219	Interpretation of disc diffusion susceptibility tests: a comparison of methods. Medical Laboratory Sciences, 1985, 42, 148-55.	0.2	1
220	Comparison of methods for the interpretation of disk diffusion susceptibility tests for augmentin. Diagnostic Microbiology and Infectious Disease, 1986, 5, 255-263.	1.8	0
221	Diagnosis and treatment of infection. Current Opinion in Infectious Diseases, 1992, 5, 415-421.	3.1	0
222	Unusual infections and development in the use of existing antimicrobial agents. Current Opinion in Infectious Diseases, 1995, 8, 261-268.	3.1	0
223	Regional Variations in the Further Management of Neutropenic Patients already Receiving Empirical Antimicrobial Therapy. Hematology, 2001, 5, 413-420.	1.5	0
224	Catheter-related infections. Lancet Infectious Diseases, The, 2005, 5, 270.	9.1	0
225	Introduction and aims. Journal of Antimicrobial Chemotherapy, 2011, 66, i3-i4.	3.0	0
226	Three major achievements of the Infections Disease Group. European Journal of Cancer, Supplement, 2012, 10, 88-93.	2.2	0
227	Editorial: Resurrecting the rubric â€˜For debateâ€™. Journal of Antimicrobial Chemotherapy, 2016, 71, 2065-2065.	3.0	0
228	Dr Tanya Parkinson, 15 June 1965â€“8 August 2016. Journal of Antimicrobial Chemotherapy, 2017, 72, 1271-1271.	3.0	0
229	Reply to Luppi et al. Clinical Infectious Diseases, 2020, 71, 3266-3266.	5.8	0
230	Reply to Herbrecht et al. Clinical Infectious Diseases, 2020, 71, 2774-2775.	5.8	0
231	Defining Invasive Aspergillosis: What the Revised EORTC/MSG Definitions Have in Store. , 2009, , 423-435.		0
232	Host impairments in patients with neoplastic diseases. , 1998, 96, 1-32.		0
233	Supportive Care in the Management of Leukaemia. , 0, , 586-602.		0